The New England Journal of Medicine (NEJM) RSS feed -- Search Results in Clinical Medicine. NEJM (https://www.nejm.org) is a weekly general medical journal that publishes new medical research findings, review articles, and editorial opinion on a wide variety of topics of importance to biomedical science and clinical practice. https://www.nejm.org/action/showPodcastsFeeds NEJM Group Mon, 26 Oct 2026 05:27:53 GMT 2026 NEJM Group en-us 1440 An oncology fellow is used to having code-status discussions with patients and families, but when her father is downed by an ocean wave, she suddenly sees the DNR question from a new perspective. https://www.nejm.org/doi/full/10.1056/NEJMp2605919?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2605919 Netana Markovitz 2026-10-24 My Father’s Code A previously healthy crop farmer presented with a 2-month history of foreign-body sensation, redness, and blurred vision in his eyes. Motile roundworms were found in the conjunctival fornices of both eyes (shown in a video). https://www.nejm.org/doi/full/10.1056/NEJMicm2609683?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2609683 Ji Eun Song, Kyuseong Jo 2026-10-24 Thelaziasis Among patients with mild stroke from large-vessel occlusion, 69.4% had a favorable functional outcome at 90 days with endovascular therapy plus medical management, as compared with 50.0% with medical management alone. https://www.nejm.org/doi/full/10.1056/NEJMoa2609149?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609149 Jianmin Liu, Tingyu Yi, Pengfei Xing, Meihua Wu, Liyong Zhang, Tuanyuan Zheng, Mingzhu Huang, Yanmin Wu, Hao Wang, Guoyong Zeng, Jinglun Li, Ya Peng, Yueqi Zhu, Yibin Fang, Xueli Cai, Jun Luo, Yuanbiao Lei, Hao Qin, Pu Fang, Yamei Tang, Guangxiong Yuan, En Wang, Xiongjun He, Xiongwei Lu, Zhentao Li, Bo Lei, Hua Cao, Xinguang Yang, Chenghua Xu, Meixia Shang, Craig S. Anderson, Zeguang Ren, Pengfei Yang, Wenhuo Chen, the MILD-MT Investigators* 2026-10-23 Trial of Endovascular Therapy for Mild Stroke with Large-Vessel Occlusion Among patients with salvageable tissue 24 to 72 hours after stroke, physical function at 90 days was better with thrombectomy than with medical care alone, but intracerebral hemorrhage and death were more common with thrombectomy. https://www.nejm.org/doi/full/10.1056/NEJMoa2609362?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609362 Pengfei Yang, Hongjian Shen, Tingyu Yi, Pengfei Xing, Junfeng Su, Changming Wen, Weiyi Zhong, Qiang Li, Yunting He, Xiaoying Chen, Song He, Xinwen Ren, Shoujiang You, Yang Zhao, Borui Wang, Yongxin Zhang, Lei Chen, Xuan Zhu, Minmin Zhang, Ying Yu, Yi Jiang, Yina Wu, Chuanchuan Wang, Xiaoxi Zhang, Wenjin Yang, Fang Shen, Lijun Wang, Meihua Huyan, Bing Tian, Wenhuo Chen, Guangxian Nan, Liyong Zhang, Huaizhang Shi, Jianfeng Han, Tong Li, Fan Zhang, Ming Wei, Chenghua Xu, Ya Peng, Jun Sun, Shouchun Wang, Hongxing Han, Hao Wang, Wenqiang Cai, Meng Zhang, Congguo Yin, Guangsen Cheng, Rong Yin, Quanbin Zhang, Guodong Xiao, Yunfeng Zhang, Sheng Liu, Hui Li, Lei Zhang, Zifu Li, Yu Zhou, Rui Zhao, Qiang Li, Charles B.L.M. Majoie, Lili Song, Yongwei Zhang, Craig S. Anderson, Jianmin Liu, the LATE-MT Investigators* 2026-10-23 Mechanical Thrombectomy 24 to 72 Hours after Large-Vessel Ischemic Stroke An interim analysis of a phase 3 randomized trial involving adults with IgA nephropathy showed that ravulizumab, a terminal complement inhibitor, led to a significantly greater reduction in proteinuria than placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2607544?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2607544 Jonathan Barratt, Youssef M.K. Farag, Kara Rice, Tobin J. Cammett, Lesley A. Inker, Hernán Trimarchi, Annette Bruchfeld, Hiddo J.L. Heerspink, Adrian Liew, Kevin Carroll, Hong Zhang, Sayna Norouzi, Shuang Hou, Sehoon Park, Miguel Ángel Pérez Valdivia, Jai Radhakrishnan, Yusuke Suzuki, Bonnie Schneider, John Marsala, Cynthia Carrillo-Infante, Stephen L. Lake, Ajay K. Singh, Stephen Nolan, Richard A. Lafayette, the I CAN Trial Group* 2026-10-23 Ravulizumab in IgA Nephropathy — Interim Analysis of a Phase 3 Trial In 2015, pivotal randomized, controlled trials established the benefit of endovascular treatment for acute ischemic stroke due to a large-vessel occlusion.1,2 The trials showed a major clinical benefit in patients presenting with relatively standard stroke features: large-vessel occlusion in the anterior circulation; relevant clinical neurologic deficit; short time... https://www.nejm.org/doi/full/10.1056/NEJMe2612692?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2612692 Gaultier Marnat 2026-10-23 Expanding the Evidence and Indications for Thrombectomy in Ischemic Stroke In this phase 3, double-blind, randomized trial involving patients with IgA nephropathy, sibeprenlimab stabilized the eGFR slope over 24 months, consistent with a reduced risk of kidney-function decline. https://www.nejm.org/doi/full/10.1056/NEJMoa2609127?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2609127 Dana V. Rizk, Jonathan Barratt, Yusuke Suzuki, Hong Zhang, Muh Geot Wong, Adrian Liew, Richard Lafayette, Vladimír Tesař, Hernán Trimarchi, Kevin Carroll, Ian S.D. Roberts, Vivekanand Jha, Alejandra Quevedo, Seung Hyeok Han, Rosnawati Yahya, Chee Kay Cheung, Raja Ramachandran, Michael Walsh, Bobby Chacko, Manuel Praga, Jin-Bor Chen, José Suassuna, Jing Xia, Lokesh Shah, Vlado Perkovic, the VISIONARY Trial Investigators Group* 2026-10-22 Sibeprenlimab in IgA Nephropathy — Final Phase 3 Trial Analysis In two trials involving patients with active Sjögren’s disease, decreases in disease activity at 48 weeks were greater with monthly ianalumab than with placebo, but differences in response rates and symptom scores were not significant. https://www.nejm.org/doi/full/10.1056/NEJMoa2601088?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2601088 Xavier Mariette, Thomas Grader-Beck, Stephanie Finzel, Elena Schiopu, Athena Papas, Valerie Devauchelle-Pensec, Monika Sopala, Xiaofeng Zeng, Ghaith Noaiseh, Tsutomu Takeuchi, Uma Kumar, Josef Hermann, Hiroki Ozawa, Robert Fox, Susan Zong, Deepak Narayanswamy, Xiaomei Li, Wen-Lin Luo, Janice Woznicki, Laurie Debonnett, Xuan Zhu, Linchen He, Franziska Matzkies, Angelika Jahreis, Devendra Kumar Jain, Brian Porter, Carol Lau, Thomas Dörner, Sara S. McCoy, Simon J. Bowman, Wolfgang Hueber, the NEPTUNUS-1 and NEPTUNUS-2 Investigators* 2026-10-22 Ianalumab for the Treatment of Patients with Sjögren’s Disease In patients with IgA nephropathy, atacicept, a human TACI–Fc fusion protein that modulates B-cell activity, slowed and stabilized the decline in the eGFR as compared with placebo. https://www.nejm.org/doi/full/10.1056/NEJMoa2610103?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2610103 Jonathan Barratt, Robert M. Brenner, Sean J. Barbour, Kirk N. Campbell, Tom Doan, Necmi Eren, Jürgen Floege, Marshall W. Fordyce, Vivekanand Jha, Zeeshan Khawaja, Beom Seok Kim, Adrian Liew, Bart Maes, Atanu Pal, Roberto Pecoits-Filho, Richard K.S. Phoon, Dana V. Rizk, Hitoshi Suzuki, Vladimír Tesař, Hernán Trimarchi, Xuelian Wei, Lixi Yu, Hong Zhang, Richard Lafayette, the ORIGIN Phase 3 Trial Investigators* 2026-10-22 Atacicept in IgA Nephropathy — Phase 3 Trial Final Efficacy Analysis Among adults with endocarditis caused by S. aureus, E. faecalis, or streptococcus species, tailored-duration antibiotic therapy led to 13 more days alive without antibiotics than standard therapy, but with a higher incidence of relapse. https://www.nejm.org/doi/full/10.1056/NEJMoa2607887?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2607887 Henning Bundgaard, Mia Pries-Heje, Julie Hjulmand, Rasmus Hasselbalch, Peter Godsk Jørgensen, Søren Fanø, Nana Køber, Christian Tuxen, Nareen Kader, Ekim Seven, Lars Ege Rasmussen, Malene Wienberg, Niels Eske Bruun, Marlene Tofterup, Magnus Rasmussen, Lindsey R. Baden, Ann Woolley, Theis Lange, Jannik Helweg-Larsen, Jonas Agerlund Povlsen, Emil Fosbøl, Claus Moser, Kasper Iversen, the POET II Investigators* 2026-10-22 Response-Tailored or Standard-Duration Antibiotic Treatment for Infective Endocarditis Adding milvexian to standard antiplatelet therapy after an acute coronary syndrome event did not lower the risk of a composite of cardiovascular death, MI, or ischemic stroke but did not increase intracranial or fatal bleeding. https://www.nejm.org/doi/full/10.1056/NEJMoa2608717?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMoa2608717 C. Michael Gibson, P. Gabriel Steg, M. Cecilia Bahit, Rasha Al-Lamee, Shamir R. Mehta, Roxana Mehran, Jeffrey I. Weitz, Shinya Goto, Jose Carlos Nicolau, Renato D. Lopes, Junbo Ge, Nebojsa Tasic, Dominick J. Angiolillo, Suzanne J. Baron, Ajay J. Kirtane, Denis Xavier, Satoshi Yasuda, Basil S. Lewis, Duk-Woo Park, Jan H. Cornel, Thomas W. Johnson, Jaroslaw Trebacz, Daniel Duerschmied, Christoph Bode, Bela Merkely, Maria Dorobantu, Dragos Vinereanu, Zuzana Motovska, Hector Bueno, Jose Luis Lopez-Sendon, Gregory Ducrocq, Giuseppe Ambrosio, Lesley Burgess, Allan Bohm, Chern-En Chiang, Joao Morais, Alan Fong, Umit Guray, Jose Luis Leiva-Pons, Pascal Vranckx, Harvey D. White, Sasko Kedev, Marco Valgimigli, Duško Cerovec, Dimitris Tousoulis, Gemma Figtree, Thuong Dung Ho, Rody G. Sy, Morten Bøttcher, Kurt Huber, Rimvydas Slapikas, Andrejs Erglis, Jack Wei Chieh Tan, Christian Pincetti, Karen S. Pieper, Kenneth W. Mahaffey, Carolyn S.P. Lam, S. Claiborne Johnston, Graeme J. Hankey, Jennifer S. Li, Luke Zheng, Ronald Aronson, Danshi Li, Ravi Notani, Philippe Vieira Pires, Thomas J. Povsic, Alistair C. Lindsay, Alexei Plotnikov, Hsiaowei Deng, Elliot S. Barnathan, Robert A. Harrington, the LIBREXIA ACS Committees and Investigators* 2026-10-22 Milvexian with Antiplatelet Therapy after Acute Coronary Syndrome Event Studies of suicidality and other acute psychiatric conditions may require participation of involuntarily hospitalized patients, but guidelines are needed to ensure that such research is ethical. https://www.nejm.org/doi/full/10.1056/NEJMms2608116?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMms2608116 Benjamin C. Silverman, Kate Gallin, Joan A. Camprodon 2026-10-22 Conducting Research with Involuntarily Hospitalized Patients — Ethical, Legal, and Regulatory Considerations New Medicaid eligibility rules will burden both beneficiaries and physicians, threaten funding for health care institutions and clinicians, and leave more U.S. residents without insurance coverage. https://www.nejm.org/doi/full/10.1056/NEJMp2608810?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2608810 Nicole Huberfeld, Paul R. Shafer 2026-10-22 Community Engagement Requirements in Medicaid — Law as a Determinant of Health Infective endocarditis has traditionally been treated with intravenous antimicrobial agents for a defined number of weeks.1 Clinicians have been understandably reluctant to use oral antimicrobial therapy or truncate the duration of treatment owing to one universally feared and potentially lethal complication: relapse of infection. In fact, no randomized... https://www.nejm.org/doi/full/10.1056/NEJMe2612352?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2612352 Daniel C. DeSimone, Larry M. Baddour 2026-10-22 Infective Endocarditis — When Is Enough Enough? A 36-year-old woman presented with a 6-year history of gradually worsening low back pain and intermittent night sweats. On examination, she had a sharp, kyphotic angulation of the lower spine. https://www.nejm.org/doi/full/10.1056/NEJMicm2607513?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2607513 Sara Pereira Henriques, Margarida Mota 2026-10-22 Spinal Tuberculosis Sjögren’s disease has long frustrated clinicians, trialists, and — most important — patients for whom effective treatments remain elusive. Glandular dysfunction causes dryness; fatigue and pain add substantially to daily burden; and systemic manifestations can affect major organs. These dimensions of disease do not necessarily track together. Management of dryness... https://www.nejm.org/doi/full/10.1056/NEJMe2610330?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2610330 Simone Negrini 2026-10-22 Ianalumab in Sjögren’s Disease — A First Step Trust is the precondition for informed consent, shared decision making, and any clinical intervention. But public trust in medicine is rapidly eroding, and it can’t be rebuilt in a single policy cycle. https://www.nejm.org/doi/full/10.1056/NEJMp2604584?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMp2604584 Robert B. Shpiner 2026-10-22 What I See before Anyone Speaks A 52-year-old man with metastatic small-cell lung cancer was evaluated in the ophthalmology clinic because of vision loss in the left eye. A blood cytomegalovirus DNA viral load was 348 IU per milliliter. A diagnosis was made. https://www.nejm.org/doi/full/10.1056/NEJMcpc2603184?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMcpc2603184 Lucia Sobrin, K. Matthew McKay, Victor Kovac, Frances Wu, Anna M. Stagner 2026-10-22 Case 30-2026: A 52-Year-Old Man with Vision Loss in the Left Eye Despite the receipt of guideline-directed medical therapies and potent antiplatelet agents, patients who have had an acute coronary syndrome event are at increased risk for a recurrent ischemic event.1,2 Considerable interest has been focused on the addition of anticoagulation to further mitigate ischemic risk in such patients. More... https://www.nejm.org/doi/full/10.1056/NEJMe2612343?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMe2612343 Debabrata Mukherjee 2026-10-22 Role for Factor XIa Inhibitors after an Acute Coronary Syndrome Event A man presented with a 3-month history of cough, dyspnea, and fatigue. CT showed a pleural effusion with thickening and enhancement of the parietal and visceral pleura. Examination of pleural fluid showed cholesterol crystals. https://www.nejm.org/doi/full/10.1056/NEJMicm2517156?rss=searchAndBrowse https://www.nejm.org/doi/full/10.1056/NEJMicm2517156 Amirmorteza Soleimani, Yasna Aghagoli 2026-10-22 Tuberculous Empyema Resulting in Pseudochylothorax